- Market Capitalization, $K 1,170,474
- Shares Outstanding, K 27,599
- Annual Sales, $ 0 K
- Annual Income, $ -12,650 K
- 60-Month Beta -1.56
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 21.95
|Period||Period Low||Period High||Performance|
| || |
+3.68 (+9.35%)since 11/10/23
| || |
+12.23 (+39.72%)since 09/11/23
| || |
+11.90 (+38.24%)since 12/09/22
The clinical-stage biotech company bounced back from a 52-week low late last week.
The biopharmaceutical company announced a stock sale that's not great news to current investors.
These three have had big-time share gains backed up by breakthrough science.
Find out how these stock rockets could continue their ascent.
These drugmakers have bucked the overall market's downward trend this year and expectations are still high.
Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.
-LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMD -A 2-year Phase 2 trial...
SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company...
LBS-008 (a/k/a Tinlarebant) is the Company’s orally administered tablet for the treatment of Stargardt disease (STGD1)There are currently no approved...
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug...
|3rd Resistance Point||44.78|
|2nd Resistance Point||43.66|
|1st Resistance Point||43.04|
|1st Support Level||41.30|
|2nd Support Level||40.18|
|3rd Support Level||39.56|